Team:SupBiotech-Paris/Bibliography

From 2009.igem.org

(Difference between revisions)
Line 8: Line 8:
</a></div>
</a></div>
</html>
</html>
 +
== Therapies ==
{|
{|
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
Line 50: Line 51:
|http://www.genetics.com.au/index.asp
|http://www.genetics.com.au/index.asp
|XXXX
|XXXX
 +
|}
 +
 +
== Vectorization ==
 +
{|
 +
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
 +
|width=120px height=40px|Chapitre
 +
|width=40px|Ref.
 +
|width=120px|Auteurs
 +
|width=560px|Titre
 +
|width=70px|Lien
|- style="background: #C0C0C0; text-align: center;"
|- style="background: #C0C0C0; text-align: center;"
Line 183: Line 194:
|Nanotoxicology and nanomedicine: making hard decisions
|Nanotoxicology and nanomedicine: making hard decisions
|2008
|2008
 +
|}
 +
 +
== Tissue Vector ==
 +
{|
 +
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
 +
|width=120px height=40px|Chapitre
 +
|width=40px|Ref.
 +
|width=120px|Auteurs
 +
|width=560px|Titre
 +
|width=70px|Lien
|- style="background: white; text-align: center;"
|- style="background: white; text-align: center;"
Line 233: Line 254:
|The thymus as a target for mycobacterial infections
|The thymus as a target for mycobacterial infections
|2007
|2007
 +
|}
 +
 +
== Cell Vector ==
 +
{|
 +
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
 +
|width=120px height=40px|Chapitre
 +
|width=40px|Ref.
 +
|width=120px|Auteurs
 +
|width=560px|Titre
 +
|width=70px|Lien
|- style="background: #C0C0C0; text-align: center;"
|- style="background: #C0C0C0; text-align: center;"
Line 296: Line 327:
|Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization
|Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization
|1997
|1997
 +
|}
 +
 +
== Therapeutic Plasmide ==
 +
{|
 +
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
 +
|width=120px height=40px|Chapitre
 +
|width=40px|Ref.
 +
|width=120px|Auteurs
 +
|width=560px|Titre
 +
|width=70px|Lien
|- style="background: white; text-align: center;"
|- style="background: white; text-align: center;"
Line 345: Line 386:
|Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature
|Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature
|2003
|2003
 +
|}
 +
 +
== Title ==
 +
{|
 +
|- style="background: grey; color:white; text-align: center; font-weight:bold; "
 +
|width=120px height=40px|Chapitre
 +
|width=40px|Ref.
 +
|width=120px|Auteurs
 +
|width=560px|Titre
 +
|width=70px|Lien
 +
 +
|- style="background: white; text-align: center;"
 +
|height=40px|
 +
|[]
 +
|
 +
|
 +
|
|- style="background: #C0C0C0; text-align: center;"
|- style="background: #C0C0C0; text-align: center;"
Line 353: Line 411:
|
|
 +
|- style="background: white; text-align: center;"
 +
|height=40px|
 +
|[]
 +
|
 +
|
 +
|
 +
 +
|- style="background: #C0C0C0; text-align: center;"
 +
|height=40px|
 +
|[]
 +
|
 +
|
 +
|
 +
 +
|- style="background: white; text-align: center;"
 +
|height=40px|
 +
|[]
 +
|
 +
|
 +
|
 +
 +
|- style="background: #C0C0C0; text-align: center;"
 +
|height=40px|
 +
|[]
 +
|
 +
|
 +
|
 +
 +
|- style="background: white; text-align: center;"
 +
|height=40px|
 +
|[]
 +
|
 +
|
 +
|
 +
 +
|- style="background: #C0C0C0; text-align: center;"
 +
|height=40px|
 +
|[]
 +
|
 +
|
 +
|
 +
 +
|- style="background: white; text-align: center;"
 +
|height=40px|
 +
|[]
 +
|
 +
|
 +
|
 +
 +
|- style="background: #C0C0C0; text-align: center;"
 +
|height=40px|
 +
|[]
 +
|
 +
|
 +
|
 +
|}
|}
|}

Revision as of 23:19, 20 October 2009

framless


Contents

Therapies

Chapitre Ref. Auteurs Titre Lien
Current Therapies [1] Lechat P. Pharmacology 2006
Current Therapies [2] Bruguerolle B. Biological rhythms and medications: a source of variability often neglected in pharmacology 2008
Current Therapies [1] Kevin J. Scanlon and al. Cancer Gene Therapy: Challenges and Opportunities 2004
Gene Therapies [2] Gouze JN and al. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer 2003
Gene Therapies [3] Centre for Genetics Education http://www.genetics.com.au/index.asp XXXX

Vectorization

Chapitre Ref. Auteurs Titre Lien
Vectorization [1] Couvreur P. L'encapsulation de médicament 2003
Vectorization [2] Andrieux K. and al. Nanotechnology and new drug 2003
Vectorization [3] Torchilin V.P. Recent Approaches to Intracellular Delivery of Drugs and DNA and Organelle Targeting 2006
Vectorization [4] Davis M.E. and al. Nanoparticle therapeutics: an emerging treatment modality for cancer 2008
Vectorization [5] Seow Y. and al. Biological Gene Delivery Vehicles: Beyond Viral Vectors 2009
Vectorization [6] Decroly E. Vectorology 2005
Vectorization [7] Robbins P.D. and al. Viral Vectors for Gene Therapy 1998
Vectorization [8] Wei M.Q. and al. Bacterial targeted tumour therapy-dawn of a new era 2008
Vectorization [9] Ryan R.M. and al. Use of bacteria in anti-cancer therapies 2005
Vectorization [10] Mehnert Solid lipid nanoparticles: Production, characterization and applications 2001
Vectorization [11] Lasic D.D. Liposomes in gene therapy 1996
Vectorization [12] Lutten J. and al. Biodegradable polymers as non-viral carriers for plasmid DNA delivery 2008
Vectorization [13] Jiskoot W. and al. Immunological Risk of Injectable Drug Delivery Systems 2009
Vectorization [14] Head M. and al. Mechanism and computer simulation of immune complex formation, opsonization, and clearance 1996
Vectorization [15] Koide H. and al. Particle size-dependent triggering of accelerated blood clearance phenomenon 2008
Vectorization [16] Ishida T. and al. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes 2005
Vectorization [17] Wang XY and al. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes 2007
Vectorization [18] Tosi M.F. and al. Innate immune responses to infection 2005
Vectorization [19] Linkov I and al. Nanotoxicology and nanomedicine: making hard decisions 2008

Tissue Vector

Chapitre Ref. Auteurs Titre Lien
Tissue Vector [1] Ronald S. and al. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies 2009
Tissue Vector [2] Clark B. Inderlied and al. The Mycobacterium avium Complex 1993
Tissue Vector [3] Nisheeth Agarwal and al. Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase 2009
Tissue Vector [4] Hunter R.L. and al. Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs 2007
Tissue Vector [5] Axelrod S and al. Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide 2008
Tissue Vector [6] Nicole N van der Wel and al. Subcellular localization of mycobacteria in tissues and detection of lipid antigens in organelles using cryo-techniques for light and electron microscopy 2005
Tissue Vector [7] Claudia Nobrega and al. The thymus as a target for mycobacterial infections 2007

Cell Vector

Chapitre Ref. Auteurs Titre Lien
Cell Vector [1] Harrison Echols and al. Genetic Map of Bacteriophage Lambda 1978
Cell Vector [2] Joseph Sambrook and al. Molecular Cloning: A Laboratory Manual (Third Edition) 2001
Cell Vector [3] Court DL and al. A New Look at Bacteriophage lambda Genetic Networks 2007
Cell Vector [4] Ortega ME and al. Bacteriophage Lambda gpNu1 and Escherichia coli IHF Proteins Cooperatively Bind and Bend Viral DNA: Implications for the Assembly of a Genome-Packaging Motor 2006
Cell Vector [5] Feiss M. and al. Bactériophage Lambda Terminase and the Mechanism of Viral DNA Packaging 2005
Cell Vector [6] Hang JQ and al. The Functional Asymmetry of cosN, the Nicking Site for Bacteriophage λ DNA Packaging, Is Dependent on the Terminase Binding Site, cosB 2001
Cell Vector [7] Becker A and al. Bacteriophage lambda DNA : The begginning of the End 1990
Cell Vector [8] Hochschild A and al. The bactériophage lambda cI protein finds an asymmetric solution 2009
Cell Vector [9] Phoebe L.Stewart1 and al. Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization 1997

Therapeutic Plasmide

Chapitre Ref. Auteurs Titre Lien
Therapeutic Plasmide [1] Ortega ME et al. Bacteriophage lambda gpNu1 and Escherichia coli IHF proteins cooperatively bind and bend viral DNA: implications for the assembly of a genome-packaging motor 2006
Therapeutic Plasmide [2] Joseph Sambrook and al. Molecular Cloning: A Laboratory Manual (Third Edition) 2001
Therapeutic Plasmide [3] Court DL and al. A New Look at Bacteriophage lambda Genetic Networks 2007
Therapeutic Plasmide [4] Feiss M. and al. Viral Genome Packaging Machines: Genetics, Structure and Mechanism 2005
Therapeutic Plasmide [5] Hang JQ and al. The Functional Asymmetry of cosN, the Nicking Site for Bacteriophage λ DNA Packaging, Is Dependent on the Terminase Binding Site, cosB 2001
Therapeutic Plasmide [6] Becker A and al. Bacteriophage lambda DNA : The begginning of the End 1990
Therapeutic Plasmide [7] Young et al. Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature 2003

Title

Chapitre Ref. Auteurs Titre Lien
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]

|}


Back to top


Retrieved from "http://2009.igem.org/Team:SupBiotech-Paris/Bibliography"